Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volenrelaxin in Adults With Chronic Kidney Disease
NCT06598631Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of volenrelaxin in chronic kidney disease (CKD) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Urine Albumin-Creatinine Ratio at 12 weeks. Planned start Oct 2024; status: withdrawn.
02
Drugs
volenrelaxin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT06598631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06598631.